Forian Inc. (Nasdaq: FORA), a provider of data analytics and information solutions, has entered a definitive merger agreement to be acquired by a consortium of investors led by Chairman and CEO Max Wygod, together with other senior executives and existing stockholders. The all-cash transaction values the company's equity at approximately $68 million and will return Forian to private ownership.
Under the agreement, Forian stockholders will receive $2.17 per share in cash, representing a premium of approximately 22.6% to the company's unaffected closing price as of August 22, 2025. The transaction was unanimously approved by the Forian Board of Directors, acting upon the recommendation of a Special Committee of independent directors formed in response to the consortium's initial proposal. The committee was advised by independent financial and legal advisors throughout the process.
The transaction is expected to close in the second quarter of 2026, subject to satisfaction of the minimum tender condition and other closing conditions. Following completion, Forian will no longer be listed on the Nasdaq Stock Market or any public exchange. The company will continue to be led by Max Wygod and the current leadership team, maintaining its headquarters in Newtown, Pennsylvania and operating under the Forian name and brand.
For business and technology leaders, this transaction represents a significant shift in the data analytics landscape. Forian provides data management capabilities and proprietary analytics solutions for life sciences, healthcare, and financial services industries, with expertise in acquiring, integrating, and commercializing large-scale healthcare data assets. The move to private ownership could allow the company greater operational flexibility and strategic freedom without quarterly public market pressures, potentially accelerating innovation in its specialized data analytics offerings.
The consortium has secured committed funding for the transaction, which is not subject to a financing condition. Houlihan Lokey Capital, Inc. served as independent financial advisor to the Special Committee, while Potter Anderson & Corroon LLP and Miles & Stockbridge PC provided legal counsel. Duane Morris LLP served as outside legal counsel to Forian, with Allen Overy Shearman Sterling US LLP, Abrams & Bayliss LLP, and Venable LLP representing the consortium.
For investors and industry observers, this transaction highlights ongoing consolidation in the data analytics sector and the appeal of specialized healthcare data capabilities. The premium offered to shareholders reflects the perceived value of Forian's proprietary technology and data assets. The company's continued focus on optimizing operational, clinical, and financial performance for healthcare and life sciences customers suggests the new ownership structure may prioritize long-term strategic investments over short-term financial metrics.
Additional information about the transaction will be available through regulatory filings with the SEC and on the company's investor relations website at forian.com/investors.
